ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Hanyang, Seoul, KOR:

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapi...

Enrolling
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Belantamab

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 20 other locations

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 29 other locations

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of and 220 other locations

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Seoul, Korea, Republic of and 53 other locations

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 143 other locations

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12)

antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 18 other locations

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Bortezomib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 118 other locations

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 135 other locations

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM5)

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GS...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: GSK3174998

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 39 other locations

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Seoul, Korea, Republic of and 265 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems